or Try an Advanced Search...

    Technical Analysis for ZLAB - Zai Lab Limited

    Grade Last Price % Change Price Change
    F 17.29 -0.23% -0.04
    ZLAB closed down 0.23 percent on Monday, July 1, 2024, on 46 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ZLAB trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    BB Squeeze Ended Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Bollinger Band Squeeze Range Contraction -0.23%
    Lower Bollinger Band Walk Weakness -0.23%
    BB Squeeze + Lower Band Touch Range Contraction -0.23%
    Older End-of-Day Signals for ZLAB ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 10 hours ago
    Up 2% about 10 hours ago
    Up 1% about 10 hours ago
    Gap Down Partially Closed 3 days ago
    Gap Down Closed 3 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ZLAB Chart by TradingView
    Basic chart:

    Profile

    Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Natural Sciences Infectious Diseases Medication Chemical Substances Autoimmune And Infectious Diseases

    Is ZLAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 13 Increases to CEO Compensation Might Be Put On Hold For Now at Zai Lab Limited (NASDAQ:ZLAB)
    Jun 11 Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
    May 23 Zai Lab doses first subject in Phase II plaque psoriasis treatment trial
    May 22 Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
    May 20 China’s NMPA approves Zai Lab’s XACDURO NDA for pneumonia
    May 20 Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
    May 17 Insider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares
    May 16 Zai Lab Announces Participation in May and June Investor Conferences
    May 14 Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
    May 13 BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
    See more ZLAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 32.52
    52 Week Low 13.48
    Average Volume 597,258
    200-Day Moving Average 21.86
    50-Day Moving Average 18.25
    20-Day Moving Average 18.78
    10-Day Moving Average 18.18
    Average True Range 0.95
    RSI (14) 39.39
    ADX 14.05
    +DI 19.90
    -DI 22.93
    Chandelier Exit (Long, 3 ATRs) 17.72
    Chandelier Exit (Short, 3 ATRs) 19.80
    Upper Bollinger Bands 20.52
    Lower Bollinger Band 17.03
    Percent B (%b) 0.07
    BandWidth 18.59
    MACD Line -0.28
    MACD Signal Line -0.02
    MACD Histogram -0.2566
    Fundamentals Value
    Market Cap 1.71 Billion
    Num Shares 98.7 Million
    EPS -3.10
    Price-to-Earnings (P/E) Ratio -5.58
    Price-to-Sales 7.25
    Price-to-Book 2.09
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 18.85
    Resistance 3 (R3) 18.93 18.48 18.59
    Resistance 2 (R2) 18.48 18.09 18.45 18.50
    Resistance 1 (R1) 17.89 17.84 18.19 17.81 18.42
    Pivot Point 17.44 17.44 17.59 17.41 17.44
    Support 1 (S1) 16.85 17.05 17.15 16.77 16.16
    Support 2 (S2) 16.40 16.80 16.37 16.08
    Support 3 (S3) 15.81 16.40 15.99
    Support 4 (S4) 15.73